Press release
2018-07-16
Xbrane Biopharma AB ("Xbrane") invites investors, analyst and media to a webinar where the recently disclosed co-development agreement with STADA Arzneimittel AG ("STADA") for Xlucane will be discussed.
In a press release dated 12 July 2018, Xbrane disclosed that a co-development agreement with STADA had been entered for Xlucane, a Lucentis® (ranibizumab) biosimilar. Xbrane now invites investors, analysts and media to participate in a webinar where Xbrane's CEO, Martin Åmark, discusses the agreement and how it affects the development of Xlucane. There will be possible to post questions during the webinar or to send them by e-mail (see contact details below) in advance. The presentation will afterwards be available on Xbrane's website, www.xbrane.com.
Presenter
Martin Åmark, CEO, Xbrane Biopharma
Date and time
Tuesday 17 July 2018, 10.00 pm CET
Webinar link
https://edge.media-server.com/m6/p/zhsmc5zf
For further information, please contact:
Xbrane Biopharma AB
Martin Åmark
Chief Executive Officer
M: +46 (0) 763-093 777
E: martin.amark@xbrane.com
About Xbrane
Xbrane Biopharma AB is a biotechnology company which develops, manufactures and produces commercial biosimilars. Xbrane has a patented protein production platform for development of biosimilars and world-leading expertise within biosimilars. Xbrane's head quarter is located in Solna, outside Stockholm, and the company has research and development facilities in Sweden and in Italy. Xbrane has been listed on Nasdaq First North since 3 February 2016 with the ticker XBRANE. Avanza Bank AB is Xbrane's Certified Adviser. For more information see www.xbrane.com.